{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:32:28Z","timestamp":1790681548180,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 AI 007502-22"],"award-info":[{"award-number":["T32 AI 007502-22"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 AI 052073-11 A1"],"award-info":[{"award-number":["T32 AI 052073-11 A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.cmi.2021.04.004","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T01:13:19Z","timestamp":1618794799000},"page":"1448-1454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection"],"prefix":"10.1016","volume":"27","author":[{"given":"Jiahe","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia L.","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew M.","family":"Hitchcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Holubar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Deresinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel W.","family":"Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2021.04.004_bib1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.idc.2014.11.005","article-title":"Treatment of Clostridium difficile infections","volume":"29","author":"Soriano","year":"2015","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.cmi.2021.04.004_bib2","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/1060028017706374","article-title":"Bezlotoxumab: could this be the answer for Clostridium difficile recurrence","volume":"51","author":"Chapin","year":"2017","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cmi.2021.04.004_bib3","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2021.04.004_bib4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","article-title":"Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial","volume":"12","author":"Cornely","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2021.04.004_bib5","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa1602615","article-title":"Bezlotoxumab for prevention of recurrent Clostridium difficile infection","volume":"376","author":"Wilcox","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2021.04.004_bib6","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1128\/AAC.00939-15","article-title":"Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection","volume":"59","author":"Gallagher","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2021.04.004_bib7","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s40273-017-0540-2","article-title":"A\u00a0systematic literature review of economic evaluations of antibiotic treatments for Clostridium difficile infection","volume":"35","author":"Burton","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.cmi.2021.04.004_bib8","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S1473-3099(17)30751-X","article-title":"Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b\/4 trial","volume":"18","author":"Guery","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2021.04.004_bib9","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/jac\/dky184","article-title":"Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged \u226560 years (EXTEND): analysis of cost-effectiveness","volume":"73","author":"Cornely","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2021.04.004_bib10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/cid\/cix809","article-title":"Cost-effectiveness of bezlotoxumab compared with placebo for the prevention of recurrent Clostridium difficile infection","volume":"66","author":"Prabhu","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.04.004_bib11","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1007\/s12325-018-0813-y","article-title":"Cost-effectiveness analysis of bezlotoxumab added to standard of care versus standard of care alone for the prevention of recurrent Clostridium difficile infection in high-risk patients in Spain","volume":"35","author":"Salavert","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.cmi.2021.04.004_bib12","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1017\/ice.2018.139","article-title":"Cost-effectiveness of three different strategies for the treatment of first recurrent Clostridium difficile infection diagnosed in a community setting","volume":"39","author":"Lam","year":"2018","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.cmi.2021.04.004_bib13","series-title":"Cost-effectiveness in health and medicine","author":"Neumann","year":"2016"},{"key":"10.1016\/j.cmi.2021.04.004_bib14","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/cid\/ciy149","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the infectious diseases society of America (IDSA) and society for healthcare epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.04.004_bib15","series-title":"ZINPLAVA\u2122 (bezlotoxumab) injection, for intravenous use","year":"2016"},{"key":"10.1016\/j.cmi.2021.04.004_bib16","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/bjs.8868","article-title":"Systematic review and meta-analysis of outcomes following emergency surgery for Clostridium difficile colitis","volume":"99","author":"Bhangu","year":"2012","journal-title":"Br J Surg"},{"key":"10.1016\/j.cmi.2021.04.004_bib17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jval.2012.11.004","article-title":"Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States","volume":"16","author":"Stranges","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.cmi.2021.04.004_bib18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/1469-0691.12046","article-title":"Can we identify patients at high risk of recurrent Clostridium difficile infection","volume":"18","author":"Kelly","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2021.04.004_bib19","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3201\/eid1802.101611","article-title":"Determining mortality rates attributable to Clostridium difficile infection","volume":"18","author":"Hota","year":"2012","journal-title":"Emerging Infect Dis"},{"key":"10.1016\/j.cmi.2021.04.004_bib20","series-title":"Actuarial life table 2017","year":"2018"},{"key":"10.1016\/j.cmi.2021.04.004_bib21","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/0002-9343(82)90786-0","article-title":"A\u00a0convenient approximation of life expectancy (the \u201cDEALE\u201d). I. Validation of the method","volume":"73","author":"Beck","year":"1982","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2021.04.004_bib22","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/0002-9343(82)90787-2","article-title":"A\u00a0convenient approximation of lifeexpectancy (the \u201cDEALE\u201d). II. Use in medical decision-making","volume":"73","author":"Beck","year":"1982","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2021.04.004_bib23","series-title":"Employer Costs for Employee Compensation for civilian workers by occupational and industry group","year":"2020"},{"key":"10.1016\/j.cmi.2021.04.004_bib24","series-title":"Pharmaceutical prices","year":"2020"},{"key":"10.1016\/j.cmi.2021.04.004_bib25","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1093\/cid\/cix1021","article-title":"Attributable healthcare resource utilization and costs for patients with primary and recurrent Clostridium difficile infection in the United States","volume":"66","author":"Zhang","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.04.004_bib26","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/WON.0000000000000339","article-title":"Clinical and economic burden of peristomal skin complications in patients with recent ostomies","volume":"44","author":"Taneja","year":"2017","journal-title":"J\u00a0Wound Ostomy Continence Nurs"},{"key":"10.1016\/j.cmi.2021.04.004_bib27","series-title":"Medical care CPI in U.S. city average, all urban consumers, not seasonally adjusted","year":"2020"},{"key":"10.1016\/j.cmi.2021.04.004_bib28","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/cid\/cit346","article-title":"Is fidaxomicin worth the cost? An economic analysis","volume":"57","author":"Bartsch","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.04.004_bib29","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1445-2197.2007.04226.x","article-title":"Is laparoscopic colectomy for cancer cost-effective relative to open colectomy","volume":"77","author":"Hayes","year":"2007","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.cmi.2021.04.004_bib30","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jval.2019.02.009","article-title":"United States valuation of EQ-5D-5L health states using an international protocol","volume":"22","author":"Pickard","year":"2019","journal-title":"Value in Health"},{"key":"10.1016\/j.cmi.2021.04.004_bib31","series-title":"Decision modelling for health economic evaluation","author":"Briggs","year":"2006"},{"key":"10.1016\/j.cmi.2021.04.004_bib32","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/neuonc\/not096","article-title":"The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States","volume":"15","author":"Messali","year":"2013","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.cmi.2021.04.004_bib33","first-page":"2020","article-title":"IDSA case-based clinical guideline overview and update","author":"Johnson","year":"2020","journal-title":"IDWeek"},{"key":"10.1016\/j.cmi.2021.04.004_bib34","doi-asserted-by":"crossref","first-page":"ofaa157","DOI":"10.1093\/ofid\/ofaa157","article-title":"Efficacy of Bezlotoxumab in participants receiving metronidazole, vancomycin, or fidaxomicin for treatment of Clostridioides (Clostridium) difficile infection","volume":"7","author":"Dubberke","year":"2020","journal-title":"Open Forum Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X21001877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X21001877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:30:07Z","timestamp":1761118207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X21001877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1198743X21001877"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2021.04.004","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2021.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}